Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 3Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Uveal Melanoma 1Nevus 1Meningeal Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Biphenotypic, Acute 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Cytarabine 13Cyclophosphamide 11fludarabine 10Filgrastim 8fludarabine phosphate 7Methotrexate 7Vincristine 6Specimen Handling 5Dexamethasone 5Biopsy 5venetoclax 4revumenib 4Granulocyte Colony-Stimulating Factor 4Doxorubicin 4Azacitidine 4Whole-Body Irradiation 3Prednisone 3Mycophenolic Acid 3Leucovorin 3Hydrocortisone 3Clofarabine 3selinexor 2merphos 2ixazomib 2blinatumomab 2aldesleukin 2X-Rays 2Vorinostat 2Topotecan 2Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Biphenotypic, Acute × Spinal Puncture × Clear all
NCT04872790 2026-05-06

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

OHSU Knight Cancer Institute

Phase 1 Active not recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡